Eli Lilly and Co. has entered an agreement to acquire CoLucid for approximately $960 million in cash. The acquisition enhances Lilly’s portfolio in pain management for migraine with a potential near-term launch. The transaction is expected to close by 1Q17, subject customary closing conditions.   CoLucid Pharmaceuticals is a public biopharma company developing an oral 5-HT1F agonist (lasmiditan) for the acute treatment of migraine. CoLucid has completed the first of two Phase III trials, and p...